Antisense oligonucleotides for therapeutic intervention

Stephen L. Eck; Gary J. Nabel

doi:10.1016/S0958-1669(05)80128-4

Antisense oligonucleotides for therapeutic intervention

Stephen L. Eck, Gary J. Nabel

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Advances have been made in defining the best target sequences for use in antisense oligonucleotide technology, and new chemical derivatives of oligonucleotides are being investigated. Although the potential use of antisense oligonucleotide agents in the treatment of neoplastic, viral and parasitic diseases continues to be explored, they are not yet suitable for administration to humans for reasons that are discussed.

Original language	English (US)
Pages (from-to)	897-904
Number of pages	8
Journal	Current Opinion in Biotechnology
Volume	2
Issue number	6
DOIs	https://doi.org/10.1016/S0958-1669(05)80128-4
State	Published - 1991
Externally published	Yes

ASJC Scopus subject areas

Biotechnology
Bioengineering
Biomedical Engineering

Access to Document

10.1016/S0958-1669(05)80128-4

Cite this

@article{2d9e281028aa4650bd421bf0a01fb666,

title = "Antisense oligonucleotides for therapeutic intervention",

abstract = "Advances have been made in defining the best target sequences for use in antisense oligonucleotide technology, and new chemical derivatives of oligonucleotides are being investigated. Although the potential use of antisense oligonucleotide agents in the treatment of neoplastic, viral and parasitic diseases continues to be explored, they are not yet suitable for administration to humans for reasons that are discussed.",

author = "Eck, {Stephen L.} and Nabel, {Gary J.}",

year = "1991",

doi = "10.1016/S0958-1669(05)80128-4",

language = "English (US)",

volume = "2",

pages = "897--904",

journal = "Current Opinion in Biotechnology",

issn = "0958-1669",

publisher = "Elsevier Limited",

number = "6",

}

TY - JOUR

T1 - Antisense oligonucleotides for therapeutic intervention

AU - Eck, Stephen L.

AU - Nabel, Gary J.

PY - 1991

Y1 - 1991

N2 - Advances have been made in defining the best target sequences for use in antisense oligonucleotide technology, and new chemical derivatives of oligonucleotides are being investigated. Although the potential use of antisense oligonucleotide agents in the treatment of neoplastic, viral and parasitic diseases continues to be explored, they are not yet suitable for administration to humans for reasons that are discussed.

AB - Advances have been made in defining the best target sequences for use in antisense oligonucleotide technology, and new chemical derivatives of oligonucleotides are being investigated. Although the potential use of antisense oligonucleotide agents in the treatment of neoplastic, viral and parasitic diseases continues to be explored, they are not yet suitable for administration to humans for reasons that are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0026290751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026290751&partnerID=8YFLogxK

U2 - 10.1016/S0958-1669(05)80128-4

DO - 10.1016/S0958-1669(05)80128-4

M3 - Article

C2 - 1367966

AN - SCOPUS:0026290751

SN - 0958-1669

VL - 2

SP - 897

EP - 904

JO - Current Opinion in Biotechnology

JF - Current Opinion in Biotechnology

IS - 6

ER -

Antisense oligonucleotides for therapeutic intervention

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this